AstraZeneca's 13 Outcomes-Based Contracts Show “Proactive" Engagement On New Models

 
• By Jessica Merrill

AstraZeneca VP-Market Access Rick Suarez talks about challenges and opportunities in the emerging area of innovative outcomes-based reimbursement contracts, and specifically two new contracts with Harvard Pilgrim for Bydureon and Brilinta.

Handshake of businessmen

More from Drug Pricing

More from Scrip